Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia

Phase 1

Completed

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions: Drug: alvocidib
Drug: cytarabine
Drug: mitoxantrone hydrochloride
Other: pharmacological study

First Posted Date: 2007-05-07

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00470197

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: cytarabine
Drug: idarubicin
Drug: lestaurtinib

First Posted Date: 2007-05-07

Last Posted Date: 2017-03-15

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 14

Registration Number: NCT00469859

Locations: 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

and more 18 locations

Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: cytarabine

First Posted Date: 2007-05-07

Last Posted Date: 2014-10-20

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 10

Registration Number: NCT00470275

Locations: 🇺🇸
Columbus Children's Hospital, Columbus, Ohio, United States
🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
Tulane Cancer Center Office of Clinical Research, Alexandria, Louisiana, United States

and more 70 locations

Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years

Phase 4

Completed

Conditions: Acute Myeloblastic Leukaemia

First Posted Date: 2007-04-23

Last Posted Date: 2010-01-05

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 100

Registration Number: NCT00464217

Locations: 🇪🇸
Hospital Xeral, Lugo, Spain
🇪🇸
Hospital General, Castellón, Spain
🇪🇸
Hospital Ciudad de Jaén, Jaen, Spain

and more 20 locations

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Phase 2

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2007-03-30

Last Posted Date: 2013-08-26

Lead Sponsor: The University of New South Wales

Target Recruit Count: 2000

Registration Number: NCT00454480

Locations: 🇬🇧
Queen's Hospital, Burton-upon-Trent, England, United Kingdom
🇬🇧
Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom
🇬🇧
Hereford Hospitals, Hereford, United Kingdom

and more 93 locations

Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: Cytarabine
Drug: Fludarabine
Drug: Oxaliplatin
Drug: Rituximab

First Posted Date: 2007-03-27

Last Posted Date: 2011-11-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT00452374

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of California-San Diego, La Jolla, California, United States

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

Phase 2

Completed

Conditions: Leukemia, Myeloid
Myelodysplastic Syndromes

Interventions: Drug: Gleevec
Drug: Ara-C

First Posted Date: 2007-03-26

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00451997

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Doxorubicin
Drug: Etoposide
Drug: Ifosfamide
Drug: Leucovorin
Drug: Methotrexate
Drug: Thalidomide
Drug: Vincristine
Drug: Mesna
Drug: Filgrastim (G-CSF)
Drug: Granisetron
Drug: Decadron

First Posted Date: 2007-03-22

Last Posted Date: 2015-11-10

Lead Sponsor: University of Miami

Target Recruit Count: 22

Registration Number: NCT00450801

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: PEG-asparaginase
Drug: Doxorubicin
Drug: Cytarabine
Drug: Methotrexate
Drug: Vincristine
Drug: Triple IT Therapy

First Posted Date: 2007-02-27

Last Posted Date: 2020-02-19

Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Target Recruit Count: 31

Registration Number: NCT00440726

Locations: 🇨🇦
Sick Kids, Toronto, Ontario, Canada
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States

and more 21 locations

ABT-751 With Chemotherapy for Relapsed Pediatric ALL

Phase 1

Terminated

Conditions: Recurrent Pediatric ALL
Acute Lymphoblastic Leukemia
Refractory Pediatric ALL
Relapsed Pediatric ALL

Interventions: Drug: ABT-751
Drug: Dexamethasone
Drug: PEG-asparaginase
Drug: Doxorubicin
Drug: Cytarabine
Drug: Methotrexate
Drug: Cyclophosphamide
Drug: 6-thioguanine

First Posted Date: 2007-02-23

Last Posted Date: 2021-03-17

Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Target Recruit Count: 9

Registration Number: NCT00439296

Locations: 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy